News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
807,897 Results
Type
Article (75077)
Company Profile (696)
Press Release (732124)
Section
Business (227570)
Career Advice (3761)
Deals (39130)
Drug Delivery (122)
Drug Development (89048)
Employer Resources (194)
FDA (17739)
Job Trends (17063)
News (387375)
Policy (38689)
Tag
Academia (2974)
Alliances (55875)
Alzheimer's disease (1365)
Approvals (17661)
Artificial intelligence (173)
Bankruptcy (391)
Best Places to Work (12571)
Biotechnology (478)
Breast cancer (200)
Cancer (1468)
Cardiovascular disease (126)
Career advice (3201)
Cell therapy (322)
Clinical research (70747)
Collaboration (526)
Compensation (269)
COVID-19 (2814)
C-suite (121)
Data (1428)
Diabetes (191)
Diagnostics (6711)
Earnings (92278)
Employer resources (167)
Events (126386)
Executive appointments (415)
FDA (18448)
Funding (454)
Gene therapy (222)
GLP-1 (718)
Government (5026)
Healthcare (20736)
Infectious disease (2915)
Inflammatory bowel disease (126)
Interviews (737)
IPO (17533)
Job creations (4967)
Job search strategy (2622)
Layoffs (494)
Legal (9859)
Lung cancer (218)
Manufacturing (236)
Medical device (14444)
Medtech (14449)
Mergers & acquisitions (21737)
Metabolic disorders (529)
Neuroscience (1722)
NextGen Class of 2024 (7618)
Non-profit (5069)
Northern California (1739)
Obesity (301)
Opinion (249)
Patents (127)
People (63232)
Pharmaceutical (141)
Phase I (21816)
Phase II (30852)
Phase III (23278)
Pipeline (532)
Postmarket research (3278)
Preclinical (9672)
Radiopharmaceuticals (258)
Rare diseases (291)
Real estate (7139)
Regulatory (25396)
Research institute (2642)
Resumes & cover letters (589)
Southern California (1508)
Startups (4177)
United States (16317)
Vaccines (668)
Weight loss (238)
Date
Today (37)
Last 7 days (632)
Last 30 days (2599)
Last 365 days (37930)
2024 (37713)
2023 (42567)
2022 (53927)
2021 (58722)
2020 (57669)
2019 (51319)
2018 (39099)
2017 (36857)
2016 (37795)
2015 (43821)
2014 (38556)
2013 (34692)
2012 (36543)
2011 (36597)
2010 (36130)
Location
Africa (1193)
Arizona (210)
Asia (47897)
Australia (8242)
California (4035)
Canada (1474)
China (322)
Colorado (184)
Connecticut (199)
Europe (108802)
Florida (550)
Georgia (146)
Illinois (454)
Indiana (244)
Maryland (684)
Massachusetts (3228)
Michigan (194)
Minnesota (316)
New Jersey (1161)
New York (1126)
North Carolina (879)
Northern California (1739)
Ohio (156)
Pennsylvania (954)
South America (1566)
Southern California (1508)
Texas (588)
Utah (116)
Washington State (436)
807,897 Results for "merck and co".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lymphoma
Merck Touts 100% Complete Response Rate for Anti-ROR1 ADC as First-Line Lymphoma Treatment
Analysts called the data “very competitive” but raised questions about safety. Merck gained ownership of the ADC when it acquired VelosBio in November 2020 for $2.75 billion.
December 9, 2024
·
2 min read
·
Tristan Manalac
Collaboration
Merck Hops Onto PD-1/VEGF Train, Committing up to $3B Plus in LaNova Deal
Despite recent enthusiasm around the PD-1/VEGF space, BMO Capital Markets analyst Evan Seigerman noted that Merck’s pact with LaNova Medicines is more “conservativism” on the pharma’s part than confirmatory of recent data in the drug class.
November 14, 2024
·
2 min read
·
Tristan Manalac
GLP-1
Merck Joins Obesity Pill Race With Up to $2B Hansoh Deal
The Hansoh deal will let Merck compete in the crowded oral GLP-1 space alongside fellow pharma giants Eli Lilly, Novo Nordisk and Roche.
December 18, 2024
·
2 min read
·
Tristan Manalac
Cancer
Merck’s Keytruda Combo Fails in Phase III Colorectal Cancer Study
Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for its combo regimen of a PD-1 blocker and an anti-LAG-3 antibody.
September 25, 2024
·
2 min read
·
Tristan Manalac
Clinical research
Merck’s Subcutaneous Keytruda Meets Expectations in Phase III
Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster goes off patent in 2028.
November 19, 2024
·
2 min read
·
Annalee Armstrong
Vaccines
CDC Panel Recommends Merck and Pfizer Pneumococcal Vaccines for Adults Aged 50–64
The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.
October 24, 2024
·
2 min read
·
Tristan Manalac
Earnings
Merck Lowers Full-Year Sales Guidance Despite Strong Overall Q3 Results
Offsetting Merck’s growth in the third quarter were disappointing revenues from its HPV vaccine Gardasil and type 2 diabetes pill Januvia, with the company on Thursday narrowing its 2024 sales and adjusted profit outlooks.
October 31, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Keytruda Redeems Itself in Head and Neck Cancer as Merck Lands Potential $1.9B I&I Collab
On the heels of Keytruda’s success in a Phase III perioperative trial for a disease where it had previously failed to improve event-free survival, Merck touts an I&I deal with UK biotech Mestag.
October 8, 2024
·
2 min read
·
Kate Goodwin
Infectious Disease
CDC Backs Merck’s Capvaxive, Tees Up Pneumococcal Competition With Pfizer
In a potential challenge to Pfizer’s Prevnar 20, Merck’s Capvaxive has been recommended by the Centers for Disease Control and Protection for use in preventing invasive pneumococcal disease in adults.
July 1, 2024
·
2 min read
·
Tristan Manalac
Policy
CDC Backs Merck’s Capvaxive, Tees Up Pneumococcal Competition With Pfizer
In a potential challenge to Pfizer’s Prevnar 20, Merck’s Capvaxive has been recommended by the Centers for Disease Control and Protection for use in preventing invasive pneumococcal disease in adults.
July 1, 2024
·
2 min read
·
Tristan Manalac
1 of 80,790
Next
